Objectives: Staphylococcus aureus survives inside eukaryotic cells. Our objective was to assess the activity of NZ2114, a novel peptidic antibiotic, against intracellular S. aureus in comparison with established antistaphylococcal agents acting on the bacterial envelope with a distinct mechanism.
Introduction
Staphylococcus aureus causes a wide spectrum of mild to severe infections in both humans and animals. 1 Several factors contribute to the persistence and recurrence of these infections, but an important feature is the ability of the bacteria to invade and survive inside phagocytes and other cells. 2 Recent studies showed no direct correlation between the accumulation of antibiotics in host cells and their activity against intracellular S. aureus, and antibiotics commonly recommended for infections caused by resistant strains, such as vancomycin and daptomycin, exhibit poor intracellular activity. 3 This supports the need to assess each drug individually for intracellular antistaphylococcal activity, especially when dealing with new compounds. NZ2114 is a variant of plectasin, a defensin found in the pezizalean fungus, Pseudoplectania nigrella. This peptide has shown a potent antimicrobial effect against various Grampositive bacteria, including resistant strains of S. aureus, 4 as its mode of action involving Lipid II and its precursors is different from that of currently used antistaphylococcal compounds. 5 Our aim was to assess NZ2114 for antistaphylococcal activity in the THP-1 monocyte model in comparison with two wellestablished and clinically used antistaphylococcal compounds 
Extracellular and intracellular dose-kill curve studies
These studies were performed as previously described. 3 For extracellular activity, bacteria were used at a density of 10 6 cfu/mL and the number of viable bacteria was determined after 24 h of incubation with antibiotics. For intracellular activity, opsonized bacteria (5×10 5 cfu/mL) were added to THP-1 monocyte cultures at a bacterium-to-monocyte ratio of 4:1. After 1 h, non-phagocytosed bacteria were removed by exposure to 50 mg/L gentamicin for 45 min. Monocytes were then resuspended in standard culture medium and a first sample taken for determination of the initial cfu content. A second sample was taken after 24 h incubation in the presence of antibiotics (378C in a 5% CO 2 atmosphere). In both cases, cfu were measured by automated colony counting and the results expressed as cfu per mL (extracellular bacteria) or mg cell protein (intracellular bacteria).
Cell cytotoxicity
The effect on viability of NZ2114, vancomycin and daptomycin on THP-1 monocytes was assessed by Trypan Blue exclusion test, with cells exposed to the compounds at up to 256 mg/L for 24 h. Standard culture medium and 70% ethanol served as negative and positive controls, respectively.
Curve-fitting and statistical analyses
For the analysis of dose-effect relationships, the Hill equation (slope¼1) was used to calculate the relative maximal efficacy (E max ), the static concentration (C s ) and the goodness of fit (R 2 ), as determined by non-linear regression using GraphPad Prism w 5.0 (GraphPad Prism Software, San Diego, CA, USA). Multiple comparisons between E max values for all three compounds were performed by one-way analysis of variance with the Tukey post-hoc test (P,0.05). Comparisons of corresponding E max values of extracellular and intracellular activities for each compound were performed using the unpaired, two-tailed t-test (P, 0.05). Analysis of covariance (Tukey's) was performed for extracellular versus intracellular concentration.
Results

Susceptibility studies
MICs of NZ2114, daptomycin and vancomycin at pH 7.4 were: 4, 1 and 2 mg/L for ATCC 25923; 2, 1 and 1 mg/L for MRSA #428; and 4, 1 and .128 mg/L for VRSA2. The activities of both NZ2114 and daptomycin were impaired by the acidic pH, with increases in MIC up to 16-fold compared with at pH 7.4. In contrast, the activity of vancomycin was unaffected by this pH change.
Extracellular concentration-effect studies
The extracellular killing effects of NZ2114, daptomycin and vancomycin at concentrations ranging from 0.001-to 128-fold the MIC over a 24 h period on susceptible strains are shown in Figure 1 and Table 1 . All three compounds exhibited a bactericidal effect (E max .3 log 10 decrease in cfu compared with the initial inoculum).
Cell toxicity
The viability of THP-1 monocytes was fully maintained in THP-1 cells exposed to NZ2114, daptomycin and vancomycin at concentrations of up to 256 mg/L (≤1% of dead cells; no difference from control medium, .99% stained cells with 70% ethanol).
Intracellular concentration -effect studies Figure 1 and Table 1 show the intracellular activities of NZ2114, daptomycin and vancomycin against S. aureus phagocytosed by THP-1 monocytes when tested over a wide range of concentrations (0.01-to 128-fold the MIC) for 24 h. The maximal relative efficacy (E max ) of all compounds was considerably reduced intracellularly when compared with the extracellular values.
Against S. aureus ATCC 25923, NZ2114 retained an E max of 21.5 log 10 cfu, a level significantly better than observed with vancomycin (20.6 log 10 kill) and daptomycin (21.0 log 10 cfu). Notably, the static concentration (C s ) of NZ2114 and of daptomycin for these strains was close to their MIC in broth. This is in contrast to vancomycin, for which the static concentration (C s ) was approximately three times its MIC in broth. Against the MRSA #428 strain, all compounds had an E max of less than 21 log 10 cfu, with a trend towards better activity with NZ2114 and daptomycin. The static concentration (C s ) of vancomycin was considerably higher than its MIC ( 7-fold), in contrast to what was observed for NZ2114 or daptomycin.
The activity of NZ2114 and daptomycin against VRSA2 was only bacteriostatic, with the corresponding static concentration (C s ) being close to the MIC in broth.
Discussion
Antibacterial peptide antibiotics are a novel class of drugs active against resistant strains, with NZ2114 representing a potential candidate for development based on its pharmacodynamic profile in a murine model. 6 The present study showed that NZ2114: (i) displayed similar extracellular and intracellular activities as daptomycin, which is long known to be a highly bactericidal anti-MRSA agent; 7 and (ii) was more effective than vancomycin against the intracellular forms of susceptible bacteria. 8 The mechanisms causing such a reduction of intracellular activity, in comparison with what is seen in broth, remain largely hypothetical. For NZ2114, however, this could be caused by the acidic environment of the phagolysosomes where intracellular S. aureus multiply in THP-1 cells. We saw, indeed, that the MIC of NZ2114 was markedly increased when the pH was lowered from 7.4 to 5.4. Yet, the intracellular activities of NZ2114 and of daptomycin remain weaker than their extracellular activities, which has been observed for most antistaphylococcal drugs so far. However, the level of maximal relative activity of NZ2114 against MSSA and MRSA compares to that of daptomycin, plectasin 9 and antistaphylococcal b-lactams (including ceftobiprole). 10 The model used has several limitations. First, there was no correlation between pharmacodynamic and pharmacokinetic parameters, since we did not assay for the intracellular drug content. Second, protein binding was not taken into account because the cellular model does not allow the serum content of the culture medium to significantly vary. Third, cells were exposed to constant concentrations of antibiotics, which is at variance with what will most likely take place in vivo if using discontinuous drug administration schedules. Yet, the neutropenic murine thigh infection model applied to NZ2114 recently 6 taught us that a static effect and a 1 log 10 cfu decrease from an initial inoculum can be obtained with drug exposure levels corresponding to free AUC 24 /MIC ratios of 28.5 and 45, respectively. Although this model is very remote from ours and deals primarily with extracellular bacteria, it is interesting to note that we observe: (i) a static effect for intracellular MSSA and MRSA with both NZ2114 and daptomycin when exposing cells for 24 h at extracellular concentrations corresponding roughly to their MIC (generating the equivalent of an AUC 24 /MIC ratio of 24); and (ii) a 1 log 10 cfu decrease for extracellular concentrations 10-fold higher. Thus, the two models eventually provide reasonably convergent results. Moreover, we also know from our studies with plectasin, in which the cell model used here could be compared with an in vivo peritonitis model, that there is a fair degree of similarity between the conclusions that can be drawn from the two sets of results. 9 The data presented here allow for a direct comparison of drugs with regard to activity. In this context, NZ2114 clearly appears superior to vancomycin and similar to daptomycin, against both vancomycin-susceptible and vancomycin-resistant staphylococci. Together with the results of animal studies, 6 this may help in its rational development to fight against a bacterium that is now a major scourge in hospital and community set-ups. E max values for all compounds [ATCC, NZ2114 had a significantly lower E max value than both daptomycin and vancomycin (P,0.05 and P,0.01, respectively); MRSA, NZ2114 had a significantly lower E max value than vancomycin (P,0.01); and VRSA, no difference in E max value between NZ2114 and daptomycin (P.0.05)].
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